CVS Health (CVS) Stock Still Looks Cheap After Fresh 340B Lawsuit Claims
CVS Health stock has delivered a 57.9% return over the past three years, yet recent valuation checks still point to the shares looking inexpensive on several measures. At the same time, fresh headlines around legal disputes and board changes keep raising questions about how much of this is already reflected in the price.
- A 57.9% gain over three years suggests CVS Health has already rewarded patient holders, so the key issue now is whether the current price still gives you enough compensation for the risks ahead.
- Expansion of CVS Health's weight management offerings, including broader GLP 1 access, may support expectations for future healthcare revenue, while lawsuits over alleged mishandling of drug program reimbursements could weigh on sentiment if investors see higher regulatory or legal risk.
- CVS Health screens as undervalued on most of Simply Wall St's checks, with the stock passing 5 of 6 valuation tests, which you can see in more detail at 5/6 valuation checks.
The issue now is whether CVS Health's current share price still offers a margin of safety after that three year run, given both the supportive growth drivers and the emerging legal and governance risks.
Is CVS Health Still Cheap on Earnings?
The P/E ratio is a useful way to think about what you are paying for each dollar of CVS Health earnings. CVS Health trades on a P/E of about 24.5x, which is above the peer group average of 19.2x but slightly below the broader Healthcare industry average of about 25.3x. That mix suggests investors are paying a premium to peers in similar businesses, yet not an excessive one versus the wider sector.
The tailored fair P/E ratio for CVS Health is 36.6x, which is higher than both the current multiple and the simple industry benchmarks. This fair ratio takes into account the company’s earnings profile, margins, scale and risk factors and points to a gap between price and what would be implied by those fundamentals. Despite recent headlines about lawsuits over drug program reimbursements, the present P/E level prices CVS Health at a discount to this modelled fair value.
On the P/E multiple, CVS Health stock appears undervalued relative to what the fair ratio suggests investors might expect to pay.
See what the numbers say about this price — find out in our valuation breakdown.
The CVS Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the CVS Health valuation puzzle leaves off and spell out which specific assumptions on growth, margins and earnings would need to hold for the stock to look meaningfully richer or cheaper than today’s price, using CVS Health's Community page as the home for those ideas. Each one presents fair value as a thesis about how the business might play out over time so you can see how that view holds up.
One of the top community narratives on CVS Health: 10% undervalued
"CVS is no longer trying to be a faster pharmacy. It’s trying to be a more complete healthcare system, and that distinction matters more than quarterly volatility suggests…"
Read one of the top narratives on CVS Health
Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!
The Bottom Line
CVS Health still screens as undervalued on market multiples, which suggests the current price bakes in a fair amount of caution on legal and governance risks. The broader valuation checks look supportive rather than stretched, even after the recent share performance. From here, the real debate is whether those risks remain contained and margins hold up as CVS Health pushes further into weight management and broader healthcare services. The key question for investors is whether the present discount is compensation for those uncertainties or a sign the market is correctly pricing a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com